Pediatrics
The FDA requires that all antidepressant drugs display a black box warning describing the potential for increased suicidal thinking and behavior when prescribed to children and adolescents with MDD and other psychiatric disorders. In short-term clinical trials the suicide risk occurred twice as frequently with antidepressant-treated children/adolescents compared to those receiving placebo (4% vs. 2%, respectively) in the first few months of treatment. Pediatric patients prescribed antidepressant drugs should be closely monitored for changes in behavior.
Bupropion, citalopram, desvenlafaxine, duloxetine, maprotiline, mirtazapine, nefazodone, paroxetine, trazodone, venlafaxine, and vilazodone are not FDA-approved for use in pediatric patients as safety and effectiveness in this age group have not been well established.
Maximum recommended doses for antidepressant drugs approved for use in pediatric patients are summarized in Table 4 . Dosages exceeding these recommendations will be reviewed. 
Duration of Therapy
There is no basis for limiting antidepressant therapy duration when used to manage MDD, OCD, GAD, PTSD, or PD as these disorders can all be characterized as chronic conditions. 
Fluoxetine has demonstrated efficacy in PMDD for up to 6 months when administered continuously and up to 3 months when administered intermittently. Paroxetine and sertraline have demonstrated efficacy in PMDD for up to 6 months and 12 months, respectively, in clinical trials. Patients should be assessed periodically to determine need for continued treatment. However, the potential exists for PMDD symptoms to worsen with advancing age until patients reach menopause. Patients responding to fluoxetine, paroxetine or sertraline therapy for PMDD may benefit from chronic administration.
Duloxetine treatment duration in diabetic NP lasting greater than 6 months has not been evaluated in clinical trials. Additionally, duloxetine efficacy in CMP beyond 13 weeks has not been established in clinical trials.
Duloxetine use lasting greater than 12 months as F therapy has not been evaluated in clinical trials. Recent clinical trials have evaluated milnacipran use for up to one year in F with sustained results in pain management. F patients should be routinely evaluated for treatment effectiveness, with milnacipran therapy tapered and discontinued if positive treatment outcomes are no longer present.
3.* Duplicative Therapy
The concurrent use of two antidepressant medications with the same spectrum of activity may not be justified. The concomitant use of two cyclic antidepressants, two MAOIs, two SNRIs, or two SSRIs will be reviewed.
The concurrent use of three or more antidepressants is not justified. Therefore, the adjunctive use of three or more antidepressants, including MAOIs, SNRIs, SSRIs, cyclic antidepressants, trazodone, bupropion, and nefazodone, will be reviewed.
4.* Drug-Drug Interactions
Patient profiles will be assessed to identify those drug regimens which may result in clinically significant drug-drug interactions.
The following drug-drug interactions summarized in Table 5 are considered clinically relevant for antidepressants. Only those drug-drug interactions identified as clinical significance level 1 or those considered life-threatening which have not yet been classified will be reviewed: 
